Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.74 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | 1.59 | |||||
| Interest Coverage | 11.46 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.15 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.9 | |||||
| 3-Year EBITDA Growth Rate | -16.7 | |||||
| 3-Year EPS without NRI Growth Rate | -21.6 | |||||
| 3-Year FCF Growth Rate | -4.7 | |||||
| 3-Year Book Growth Rate | 3.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 0.57 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.83 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.62 | |||||
| 9-Day RSI | 68.54 | |||||
| 14-Day RSI | 57.11 | |||||
| 6-1 Month Momentum % | 29.77 | |||||
| 12-1 Month Momentum % | 21.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | |||||
| Quick Ratio | 2.14 | |||||
| Cash Ratio | 1.25 | |||||
| Days Inventory | 203.01 | |||||
| Days Sales Outstanding | 71.1 | |||||
| Days Payable | 68.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 9.3 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.15 | |||||
| Operating Margin % | 28.55 | |||||
| Net Margin % | 27.64 | |||||
| ROE % | 25.03 | |||||
| ROA % | 11.81 | |||||
| ROIC % | 12.1 | |||||
| ROC (Joel Greenblatt) % | 77.65 | |||||
| ROCE % | 18.29 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.77 | |||||
| Forward PE Ratio | 18.53 | |||||
| PE Ratio without NRI | 14.77 | |||||
| Shiller PE Ratio | 14.49 | |||||
| Price-to-Owner-Earnings | 12.95 | |||||
| PS Ratio | 4.1 | |||||
| PB Ratio | 3.27 | |||||
| Price-to-Tangible-Book | 8.31 | |||||
| Price-to-Free-Cash-Flow | 19.53 | |||||
| Price-to-Operating-Cash-Flow | 17.71 | |||||
| EV-to-EBIT | 11.91 | |||||
| EV-to-Forward-EBIT | 16.64 | |||||
| EV-to-EBITDA | 10.39 | |||||
| EV-to-Forward-EBITDA | 14.17 | |||||
| EV-to-Revenue | 4.2 | |||||
| EV-to-Forward-Revenue | 4.65 | |||||
| EV-to-FCF | 20.01 | |||||
| Price-to-Projected-FCF | 0.87 | |||||
| Price-to-Median-PS-Value | 0.79 | |||||
| Price-to-Graham-Number | 2.34 | |||||
| Earnings Yield (Greenblatt) % | 8.4 | |||||
| Forward Rate of Return (Yacktman) % | 0.47 |
